Scandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to shares
Scandion Oncology A/S ("Scandion" or the "Company") has carried out a rights issue of approximately SEK 236 million. Today, on 6 January 2021, the share capital increase and updated articles of association have been registered with the Danish Business Authority.
The last day of trading in paid subscribed shares (BTAs) is 12 January 2021. BTAs will be converted to shares on 18 January 2021 and the ISIN code for the BTAs will be merged with the permanent ISIN code on 18 January 2021. The newly issued shares are expected to be delivered to the shareholders’ securities accounts on 18 January 2021.
Following registration of the new shares with the Danish Business Authority, the Company's share capital has increased by DKK 787,320.8280 to a total of DKK 2,361,962.4840. The number of shares and voting rights in the Company has increased by 10,711,848 shares and voting rights to a total of 32,135,544 shares and voting rights.
The updated articles of association of the Company are available on the Company's website, www.scandiononcology.com.
For further information, please contact:
Bo Rode Hansen, CEO
Phone: +45 38 10 20 17
E-mail: [email protected]
The information was provided by the contact person above for publication on 6 January 2021.
About Scandion Oncology
Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Ticker code: SCOL
ADDvise acquires Medisuite, LLC
ADDvise Group AB has today entered into a share purchase agreement with the owner of Medisuite LLC regarding the acquisition of all the outstanding shares of Medisuite, LLC in accordance with the letter of intent communicated via a press release dated 24th May 2021. Closing of the acquisition is exp...
ADDvise förvärvar Medisuite, LLC
Medisuite är ett amerikanskt online-apotek, baserat i Cary, North Carolina, som specialiserat sig på läkemedel inom segmentet ”men’s health” för behandling av cancer, inkontinens och impotens. Bolaget har licenser att distribuera läkemedel i samtliga USA:s delstater förutom två. Bedömningen är att B...
Kallelse till årsstämma i Biovica International AB
Information med anledning av coronavirusetBolaget värnar om sina aktieägares och anställdas hälsa och välbefinnande. Det är viktigt för Bolaget att ta ett samhällsansvar och bidra till att begränsa risken för smittspridning av Covid‑19. Mot bakgrund av den extraordinära situation som råder kommer år...
Notice of annual general meeting in Biovica International AB
Information with respect to the coronavirusThe Company is mindful of the health and well-being of its shareholders and employees. It´s important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the Covid-19. Due to the extraordinary situation the a...